A systematic review found that phage therapy is effective and safe for treating infections caused by ESCAPE bacteria, pathogens that are most often resistant to antibiotics and are responsible for the majority of hospital-acquired infections.
More than 33,000 people died in the EU and the European Economic Area (EU/EEA) due to antibiotic-resistant bacterial infections in 2015 alone.
In October 2018, The Lancet published the final report on the international PhagoBurn project, which aimed to evaluate the clinical potential of bacteriophages in the treatment of burn wounds infected with Escherichia coli and Pseudomonas aeruginosa.
A liposome can become a "Trojan horse" that will help bacteriophages enter cells and destroy intracellular bacterial pathogens.
In October 2018, Credence Research (USA) published the report “Bacteriophage Market - Growth, Future, Competitive Analysis, 2018-2026,” which analyzed the key trends in the global bacteriophage market.
IDWeek, the largest annual American forum dedicated to infectious diseases, took place in San Francisco from October 3-7, 2018. Phage therapy as a treatment for antibiotic-resistant infections was the topic of one of the IDWeek plenary sessions.
The 2018 Nobel Prize in Chemistry was awarded for the development of methods for the directed evolution of peptides and proteins, in particular phage display technology. What is its essence? How do phages aid in the development of modern medicines?
At the Pasteur Institute (France), the influence of host immunity on the effectiveness of phage therapy of acute pneumonia caused by a multidrug-resistant strain of Pseudomonas aeruginosa was studied in mice.
Twenty-one patients in seven hospitals with severe, life-threatening bacterial infections that were unresponsive to antibiotics were given phage preparations against Staphylococcus aureus or Pseudomonas aeruginosa as part of an open-access program.
Seasonal and daily dynamics of the population of the pathogenic bacterium Burkholderia pseudomallei in the natural environment largely depends on bacteriophages
Every year, about a million people die from bacterial infections resistant to most antibiotics. Which "superbugs" are the most common and dangerous?
A rapid test based on a genetically modified bacteriophage has been developed in the United States to detect pathogenic E. coli in water.
In July 2018, the Journal of Trauma and Acute Care Surgery published a review devoted to the history and prospects of using bacteriophages in military medicine.
The journal Cell published two papers by independent teams of authors devoted to the mechanisms by which bacteriophages resist the bacterial defense system CRISPR-Cas. Both papers indicate that bacteriophages can cooperate to overcome bacterial immunity.
Global warming and population growth could accelerate the arrival of a "post-antibiotic era" in which humanity loses control over infectious diseases.
American scientists have proposed a new system for delivering bacteriophages to the lungs. The system could help treat chronic pneumonia caused by antibiotic-resistant pathogens.
The fifth workshop of the European Molecular Biology Organization (EMBO ) was held in Wroclaw, Poland, a city that has been one of the world's centers for research into bacteriophages as therapeutic agents for over 60 years.
At the annual meeting of the American Society of Nutrition, the results of the first clinical trial in the Western Hemisphere on the use of bacteriophages in the treatment of intestinal disorders - the Bacteriophage for Gastrointestinal Health (PHAGE) Study - were presented.
